Company news

Noxopharm Ltd. news in 2019

Noxopharm Ltd.'s news releases, calls and decks from 2019, newest first.

View company

DARRT-1 Clinical Data Webinar

December 19, 2019

Nyrada IPO Offer Fully Subscribed

December 16, 2019

Lodgement of Nyrada Inc Supplementary Prospectus

December 8, 2019

Nyrada Inc Initial Public Offering Opens

December 3, 2019

Positive DARRT-1 Data in Late-Stage Prostate Cancer

December 2, 2019

Lodgement of Nyrada Inc Prospectus - Initial Public Offering

November 26, 2019

Noxopharm Announces Appointment of Chief Commercial Officer

November 6, 2019

Appendix 4C - Quarterly

October 29, 2019

Dr Graham Kelly to Assume CEO Role

October 27, 2019

Durable Anti-Cancer Effect Confirmed in DARRT-1 Study

October 20, 2019

Potential Fundamental Change in Treatment of Brain Cancer

October 17, 2019

Further Review Shows Major Clinical Benefits from Veyonda

September 30, 2019

Veyonda and Radiotherapy Profiled at Key Oncology Meeting

September 17, 2019

Appendix 4E and Audited Financial Statements FY19

August 29, 2019

More Evidence that Veyonda Enhances RT in Prostate Cancer

August 27, 2019

NOX Receives FY19 Federal Government R&D Tax Rebate

August 23, 2019

Pre-Clinical Evidence Confirms Veyonda Abscopal Effect

August 21, 2019

Noxopharm August 2019 Corporate Presentation

August 6, 2019

NOX Announces AU$26 Million Funding Facility

July 19, 2019

Conference Hears of Positive Interim Data from LuPIN Trial

June 25, 2019

Promising Data Leads to Expansion of LuPIN Trial

May 22, 2019

LuPIN Trial Demonstrates High Rates of Response

May 20, 2019

DARRT Treatment Has Lasting Disease Control at Six Months

May 2, 2019

Veyonda and Immuno-Oncology Effect Explained

April 28, 2019

Idronoxil Confirmed as New Immuno-Oncology Drug

April 16, 2019

Veyonda Chemotherapy Enhancement Program to be Expanded

April 9, 2019

KZA: Kazia sells stake in Noxopharm

March 19, 2019

Noxopharm to expedite Veyonda Clinical Program

February 20, 2019

FNN interview with Nox Chief Medical Officer on Interim Data

February 6, 2019

Veyonda and Radiotherapy Delivers Clinical Benefits

February 5, 2019

Principal Investigator Discusses LuPIN-1 Study

January 13, 2019

Decks in 2019